Literature DB >> 1806629

The influence of different relapse criteria on the assessment of long-term efficacy of sertraline.

S A Montgomery1, D P Doogan, R Burnside.   

Abstract

The treatment of depression with antidepressant agents must be continued beyond the acute phase, until the response is complete. The precise length of this continuation phase is still debated, but most authors estimate that it should last for between 4-6 months after apparent recovery. If antidepressants are withdrawn sooner, the original depression will return (relapse) in a proportion of patients. Relapse rates on placebo are high, whether patients are first-time or recurrent depressives. Most depressions are recurrent and long-term treatment therefore ensures that the changes of a new episode of illness developing are reduced. The importance of this aspect of efficacy is recognized and new antidepressants are being tested in long-term prophylactic studies. A long-term efficacy study has shown that sertraline was significantly more effective than placebo in preventing both relapse and recurrence.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1806629     DOI: 10.1097/00004850-199112002-00006

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  5 in total

Review 1.  Continuation and maintenance therapy of early-onset major depressive disorder.

Authors:  Graham J Emslie; Taryn L Mayes; Maryse Ruberu
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 2.  Constraints on antidepressant prescribing and principles of cost-effective antidepressant use. Part 2: Cost-effectiveness analyses.

Authors:  J A Henry; C A Rivas
Journal:  Pharmacoeconomics       Date:  1997-06       Impact factor: 4.981

Review 3.  The selective serotonin reuptake inhibitor sertraline: its profile and use in psychiatric disorders.

Authors:  G MacQueen; L Born; M Steiner
Journal:  CNS Drug Rev       Date:  2001

Review 4.  Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder.

Authors:  D Murdoch; D McTavish
Journal:  Drugs       Date:  1992-10       Impact factor: 9.546

5.  The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study.

Authors:  Stuart A Montgomery; Lucilla Mansuy; Adam C Ruth; Dayong Li; Carl Gommoll
Journal:  Int Clin Psychopharmacol       Date:  2014-01       Impact factor: 1.659

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.